Cargando…

The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors

BACKGROUND: Current large-scale cancer sequencing projects have identified large numbers of somatic mutations covering an increasing number of different cancer tissues and patients. However, the characterization of these mutations at the structural and functional level remains a challenge. RESULTS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stehr, Henning, Jang, Seon-Hi J, Duarte, José M, Wierling, Christoph, Lehrach, Hans, Lappe, Michael, Lange, Bodo MH
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3123651/ https://www.ncbi.nlm.nih.gov/pubmed/21575214 http://dx.doi.org/10.1186/1476-4598-10-54

Ejemplares similares

Predictive Modeling of Drug Treatment in the Area of Personalized Medicine
por: Ogilvie, Lesley A., et al.
Publicado: (2015)

Models of Models: A Translational Route for Cancer Treatment and Drug Development
por: Ogilvie, Lesley A., et al.
Publicado: (2017)

Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics
por: Haupt, Armin, et al.
Publicado: (2012)

GeNGe: systematic generation of gene regulatory networks
por: Hache, Hendrik, et al.
Publicado: (2009)

ConsensusPathDB—a database for integrating human functional interaction networks
por: Kamburov, Atanas, et al.
Publicado: (2009)

Defining an Essence of Structure Determining Residue Contacts in Proteins
por: Sathyapriya, R., et al.
Publicado: (2009)

Tumor-Suppressor Genes and Oncogenes
Publicado: (1993)

Oncogenes and tumor-suppressor genes.
por: Lehman, T A, et al.
Publicado: (1991)

Oncogenic mechanisms of HOXB13 missense mutations in prostate carcinogenesis
por: Cardoso, Marta, et al.
Publicado: (2016)

Modeling of miRNA and Drug Action in the EGFR Signaling Pathway
por: Li, Jian, et al.
Publicado: (2012)

Residue contact-count potentials are as effective as residue-residue contact-type potentials for ranking protein decoys
por: Bolser, Dan M, et al.
Publicado: (2008)

Optimal contact definition for reconstruction of Contact Maps
por: Duarte, Jose M, et al.
Publicado: (2010)

RUNX family: Oncogenes or tumor suppressors
por: Otálora-Otálora, Beatriz Andrea, et al.
Publicado: (2019)

Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer?
por: Minde, David P, et al.
Publicado: (2011)

PDBWiki: added value through community annotation of the Protein Data Bank
por: Stehr, Henning, et al.
Publicado: (2010)

ConsensusPathDB: toward a more complete picture of cell biology
por: Kamburov, Atanas, et al.
Publicado: (2011)

Understanding protein structural changes for oncogenic missense variants
por: Hernandez, Rolando, et al.
Publicado: (2021)

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors
por: Iyer, Sudarshan R, et al.
Publicado: (2023)

Characterization on the oncogenic effect of the missense mutations of p53 via machine learning
por: Pan, Qisheng, et al.
Publicado: (2023)

Identification and analysis of mutational hotspots in oncogenes and tumour suppressors
por: Baeissa, Hanadi, et al.
Publicado: (2017)

Angiomotin Family Members: Oncogenes or Tumor Suppressors?
por: Lv, Meng, et al.
Publicado: (2017)

SIRT3: Oncogene and Tumor Suppressor in Cancer
por: Torrens-Mas, Margalida, et al.
Publicado: (2017)

A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor
por: Rodrigue, Amélie, et al.
Publicado: (2019)

Oncogenes and tumor-suppressor genes in mesothelioma--a synopsis.
por: Lechner, J F, et al.
Publicado: (1997)

Genetic Basis for Carcinogenesis. Tumor Suppressor Genes and Oncogenes
por: Rabbitts, P.
Publicado: (1992)

Is miR-29 an oncogene or tumor suppressor in CLL?
por: Pekarsky, Yuri, et al.
Publicado: (2010)

IGF-Binding Protein 2 – Oncogene or Tumor Suppressor?
por: Pickard, Adam, et al.
Publicado: (2015)

RhoB: Team Oncogene or Team Tumor Suppressor?
por: Ju, Julia A., et al.
Publicado: (2018)

Tumor Suppressors Having Oncogenic Functions: The Double Agents
por: Datta, Neerajana, et al.
Publicado: (2020)

Somatic selection distinguishes oncogenes and tumor suppressor genes
por: Chandrashekar, Pramod, et al.
Publicado: (2019)

Novel oncogenes and tumor suppressor genes in hepatocellular carcinoma
por: Wang, Fang, et al.
Publicado: (2021)

Oncogenic and tumor suppressor function of MEIS and associated factors
por: GİRGİN, Birkan, et al.
Publicado: (2020)

Monte Carlo analysis of an ODE Model of the Sea Urchin Endomesoderm Network
por: Kühn, Clemens, et al.
Publicado: (2009)

Association between tobacco substance usage and a missense mutation in the tumor suppressor gene P53 in the Saudi Arabian population
por: Almutairi, Mikhlid H., et al.
Publicado: (2021)

A Saccharomyces cerevisiae model and screen to define the functional consequences of oncogenic histone missense mutations
por: Lemon, Laramie D, et al.
Publicado: (2022)

Genomic imbalances pinpoint potential oncogenes and tumor suppressors in Wilms tumors
por: Krepischi, A. C. V., et al.
Publicado: (2016)

Oncogenes and Tumor Suppressors Regulate Glutamine Metabolism in Cancer Cells
por: Kim, Min Hyun, et al.
Publicado: (2013)

An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes
por: Mohankumar, Kumarasamypet M., et al.
Publicado: (2015)

Oncogenes and tumor suppressor genes: comparative genomics and network perspectives
por: Zhu, Kevin, et al.
Publicado: (2015)

Bioinformatic Analysis of Circadian Expression of Oncogenes and Tumor Suppressor Genes
por: Salavaty, Abbas, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ejub7bk2b5v7pmjadvr8ohi67m